Mobile

A phase II, open, single centre, exploratory study to evaluate the safety and immunogenicity of one booster dose of a GSK Biologicals’ Hepatitis B vaccine Engerix™-B or a of GSK Biologicals’ HIV candi...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-012223-29

A phase II, open, single centre, exploratory study to evaluate the safety and immunogenicity of one booster dose of a GSK Biologicals’ Hepatitis B vaccine Engerix™-B or a of GSK Biologicals’ HIV candidate vaccine (732461), administered intramuscularly, in conjunction with the administration of a single oral dose of chloroquine in healthy adults

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the effect of chloroquine on a specific CD8+ T cell response to the F4co/AS01B candidate vaccine at Day 14. • To evaluate the reactogenicity and safety of a booster dose of the investigational vaccines.

Critère d'inclusion

  • Immunisation against Hepatitis B and HIV in healthy adults aged between 18-52 years old, inclusive

Liens